Table 2.
Outcomes after salvage therapy
| Entire sample (n = 62) |
Sorafenib Group (n = 38) | Non-sorafenib Group (n = 24) | P | |
|---|---|---|---|---|
| CRc rate, No. (% [95% CI]) |
32 (51.6 [39.5–63.6]) |
25(65.8 [49.9–78.8]) |
7(29.2 [14.9–49.2]) |
*0.005 |
| OS | ||||
| Median, months (95% CI) | 12.8(3.2–22.5) | 18.4(0-50.8) | 4.8(2.0-7.6) | |
| 1-year OS, % (95% CI) | 51.6(40.6–65.7) | 63.2(49.5–80.5) | 33.3(18.9–58.7) | *0.016 |
| Estimated 2-year OS, % (95% CI) | 35.5(25.4–49.6) | 47.4(33.9–66.2) | 16.7(6.8–40.8) | *0.006 |
| EFS | ||||
| Median, months (95% CI) | 4.3(0-11.4) | 11.4(0-32.2) | 2.3(0.2–4.3) | |
| 1-year EFS, % (95% CI) | 40.3(29.8–54.6) | 50.0(36.4–68.7) | 25.0(12.5–50.0) | *0.037 |
| Estimated 2-year EFS, % (95% CI) | 33.9(23.9–48.0) | 44.7(31.4–63.7) | 16.7(6.8–40.8) | *0.012 |
Abbreviations: CRc, composite complete remission; OS, overall survival; EFS, event-free survival; * P<0.05